On January 24, 2022, BenchSci announced its US$50 million Series C financing round led by funding round led by iNovia Capital and TCV. Bringing their total investment to $123 million, BenchSci will expedite the expansion of its transformative AI-powered software platform that accelerates research in top pharmaceutical companies and over 4,500 leading research centers worldwide.
BenchSci is a global leader in machine learning applications for novel medicine development.
Osler, Hoskin & Harcourt LLP advised BenchSci with a team consisting of Chad Bayne, Justin Dharamdial, Jeremy Lin, Ferial Fekri (Emerging & High Growth Companies) and Christopher Sheridan (Tax).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Associate, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Toronto
Partner, Emerging and High Growth Companies, Toronto
